Skip to content
FFocal
Menu

Public example · synthetic, read-only proof

KRAS G12D inhibitors in pancreatic cancer

Inspect a bounded Trial Landscape example with named registry records, source links, freshness, and visible limits. This synthetic page is for review, not a customer workspace.

Representative / partial coverage

Scope
KRAS G12D inhibitors including pancreatic-cancer cohorts
Primary source
ClinicalTrials.gov registry records
Freshness
Source data checked
Coverage
Three representative records; wider registry coverage remains partial
Methodology and evidence limits
Methodology
Review representative ClinicalTrials.gov records against the interpreted cohort scope.
Freshness
Focal source data checked . Each record keeps its own registry update date.
Coverage
The three named records are representative. Wider registry coverage is partial and not exhaustive.
Limitations
Registered endpoints are planned measures, not observed results. This example does not establish efficacy, causality, later-stage, or comparative precedent.

Evidence types in this example

Source fact
Named registry status, endpoint text, and update dates stay linked to each ClinicalTrials.gov record.
Normalised value
Phase and recruitment status use consistent display categories.
Deterministic metric
Three representative records; two Recruiting, one Terminated; all Phase 1.
Focal interpretation
This bounded example does not represent later-stage or comparative precedent and does not establish efficacy.

Source records

Three named ClinicalTrials.gov records

Registry identity, status, update date, registered context, and endpoint boundaries stay beside each source link. These records are a representative, partial view.

  1. Clinical trial registry · ClinicalTrials.gov

    RMC-9805 · NCT06040541

    Phase 1 · Recruiting

    Advanced KRAS G12D-mutant solid tumours; conditions include pancreatic ductal adenocarcinoma, non-small-cell lung cancer, and colorectal cancer.

    Lead sponsor
    Revolution Medicines, Inc.
    Registry update
    Endpoint boundary
    Primary focus is adverse events and dose-limiting toxicities; activity measures are secondary.
    NCT06040541 on ClinicalTrials.gov (opens in a new tab)

  2. Clinical trial registry · ClinicalTrials.gov

    MRTX1133 · NCT05737706

    Phase 1 · Terminated

    Advanced solid tumours with KRAS G12D; pancreatic adenocarcinoma is an included condition or cohort.

    Lead sponsor
    Mirati Therapeutics Inc.
    Registry update
    Endpoint boundary
    Phase 1 focus was dose-limiting toxicity and treatment-related adverse events.
    NCT05737706 on ClinicalTrials.gov (opens in a new tab)

  3. Clinical trial registry · ClinicalTrials.gov

    ASP3082 · NCT05382559

    Phase 1 · Recruiting

    KRAS G12D-mutant solid tumours; includes treatment-naive pancreatic cancer combination cohorts and other solid-tumour cohorts.

    Lead sponsor
    Astellas Pharma Inc.
    Registry update
    Endpoint boundary
    Primary focus is dose-limiting toxicities, adverse events, and safety; objective response rate and duration of response are secondary outcomes.
    NCT05382559 on ClinicalTrials.gov (opens in a new tab)PubMed · PMID 41879829 (opens in a new tab)DOI 10.1056/NEJMoa2600752 (opens in a new tab)

Evidence boundary

Registered endpoints are planned measures, not observed results. The representative three-record view does not establish efficacy, causality, later-stage or comparative precedent, or complete coverage.